Philips has officially declared compatibility for Imricor’s interventional MR devices with its magnetic resonance systems, enabling commercial clinical use and collaboration at a leading cardiology congress.
- Philips issues compatibility declaration for Imricor iMR products
- Declaration covers multiple Philips MR system models and software versions
- Enables NorthStar system operation at Philips iMR clinical sites
- Imricor and Philips to co-sponsor educational sessions at ESC Congress 2026
- Partnership signals growing maturity and market readiness of iMR technology
Philips Confirms Compatibility for Imricor iMR Devices
Philips Medical Systems Nederland B.V., a heavyweight in medical imaging, has issued a Third Party Product Compatibility Declaration for Imricor Medical Systems’ interventional magnetic resonance (iMR) products. This formal endorsement covers Imricor’s devices working with five initial Philips MR systems and four system upgrades running software version R12.1.1 or higher. It’s a crucial commercial milestone that unlocks the ability for Imricor’s NorthStar mapping and guidance system to operate seamlessly within Philips MR environments.
Unlocking Clinical Installations at Premier iMR Sites
The compatibility declaration effectively clears the path for Imricor to install its latest technology in Philips-based iMR labs, including the prestigious German Heart Center of Charité in Berlin. Under the leadership of Professors Dr Gerhard Hindricks and Dr Sebastian Kelle, these sites can now integrate NorthStar-guided procedures, which promise enhanced real-time MR imaging for cardiac interventions. Imricor’s Chair and CEO, Steve Wedan, highlighted the significance of this step, describing it as the final hurdle to expanding iMR procedures at Philips sites.
Joint Presence at ESC Congress 2026
Further cementing their collaboration, Imricor and Philips will co-sponsor interventional MR tutorial sessions at the European Society of Cardiology (ESC) Congress in Munich this August. Led by Professor Steven Chamuleau of Amsterdam University Medical Center, these sessions will cover practical aspects of setting up iMR labs, real-world clinical experiences with MR-guided electrophysiology and ablation, and broader cardiovascular interventions such as cardiac catheterisation. The partnership reflects a shared confidence in the readiness and commercial potential of iMR technology.
Imricor’s Growing Commercial Footprint
This compatibility announcement dovetails with Imricor’s recent US commercial launch and regulatory progress, including FDA clearances for pediatric use and ongoing submissions for additional devices. The company’s VP of Marketing and Business Development, Nick Twohy, emphasised the strategic importance of Philips’ commitment, suggesting it signals a broader market opportunity for iMR products as the technology matures. Imricor’s product suite, including the NorthStar Mapping System and Vision-MR Ablation Catheters 2.0, is already approved in several international markets, positioning the company well for global expansion.
Bottom Line?
Philips’ compatibility declaration is a pivotal enabler for Imricor’s commercial expansion in iMR, but the pace of clinical adoption and partnership outcomes at key sites will be critical to watch.
Questions in the middle?
- How quickly will Philips-based iMR sites begin installing and using Imricor’s NorthStar system?
- What impact will the ESC Congress sessions have on clinician adoption and awareness of iMR procedures?
- Could this compatibility lead to deeper strategic or commercial partnerships between Philips and Imricor?